Today, we're delighted to announce our collaboration with Biotheus Inc., aiming to discover bispecific proteins targeting immune modulators and inflammatory pathways in cardiovascular disease. Details in our press release: brbio.com/bitterroot-bio… #Innovation #collaboration

Curious to learn more about our First-in-Human Study of BRB-002? Check out our press release here: brbio.com/bitterroot-bio… #BitterrootBio #BRB002 #FirstinHuman #heartdisease #cardiovascular #drugdevelopment

Join us in welcoming Georgette Verdin as our new Chief People Officer and Sherwin Chen as our new Chief Legal Officer and Corporate Secretary! Read more about new team members here: brbio.com/bitterroot-bio… #WeAreBitterroot #BitterrootBio

On Global Running Day, we were inspired to celebrate our love of running by lacing up together and supporting the AHA with every mile. Here’s to healthier hearts! #GlobalRunningDay #HealthyHearts #RunWithTheWorld #CVD #BitterrootBio

On Sept 24, our CMO Craig Basson, MD, PhD, will join a panel at the World Medical Innovation Forum #WMIF2024 to discuss “The Innovation Gap: Metabolic Drugs & Related Diseases.” Don’t miss insights from this exciting talk! #innovation #cardioimmunology

Enrollment is complete for our Phase 1 study of BRB-002 in healthy volunteers. Topline findings are expected in early 2025, with our Phase 2 trial in patients with atherosclerosis to follow. All thanks to our participants, teams, and partners! Read more: bit.ly/3YG3a0k

Our company leaders will be participating at the upcoming Jefferies London Healthcare Conference on November 20th and 21st. Looking forward to joining global healthcare leaders at one of the largest healthcare-dedicated conferences in Europe! #JefferiesHealthcare #BitterrootBio

We’re grateful to our team and our partners for their dedication and support as we advance our clinical studies in service of people suffering from atherosclerosis and cardiovascular disease. Wishing you a Thanksgiving holiday filled with gratitude. Happy Thanksgiving!

Bitterroot Bio will be at Evercore’s HealthCONx Conference on Dec. 3rd in Coral Gables. We are looking forward to connecting with industry leaders to help drive the future of cardiovascular care forward. #HealthCONx #HealthcareInnovation

Bitterroot Bio is excited to join academic, industry, regulatory, and cardiovascular patient representatives at the CVCT Forum this week in Washington, D.C.! #CVCTForum #BitterrootBio

Thank you for the dedication of our talented Team and Partners. We look forward to a joyful season and a 2025 filled with heart, and transformative progress for cardiovascular patients everywhere. Cheers! #Bitterrootforward

Bitterroot Bio Reports Data on Safety and Target Engagement from Phase 1 First-in-Human Study of BRB-002 in Healthy Volunteers. Read the full Press Release here: bit.ly/3WyzSzB

We will be at the TD Cowen Health Care Conference in Boston, where our team will meet with industry leaders to discuss our efforts to improve the lives of patients with cardiovascular disease. Learn more about our science at brbio.com #cardioimmunology

Come see us present results from the Phase 1 study of BRB-002 at ACC’s Annual Scientific Session in Chicago! #ACC2025

It's not all pipettes and protocols! The Bitterroot team stepped out to enjoy the Stanford / Berkeley baseball game last Friday. Teamwork and heart are what drive us all forward!

Today, we presented foundational data from our Phase 1 study of BRB-002, a novel protein therapy in development for the treatment of ASCVD, demonstrating encouraging safety at all tested doses, with robust target engagement. #ACC25 View our poster: brbio.com/wp-content/upl…

An encore display of our ACC poster detailing our BRB-002 Phase 1 results will be held at the Stanford Drug Discovery Symposium on April 28 & 29. Come check it out! #ASCVD #Cardioimmunology #AmericanCollegeofCardiology

We will be at the Jefferies Global Healthcare Conference in New York City, where we will connect with industry leaders to share our vision for improving the lives of patients with cardiovascular disease. #cardioimmunology #ASCVD #JefferiesHealthcareConference